Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
86%(6 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
6
67%
Ph phase_2
3
33%

Phase Distribution

6

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
3(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
77.8%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (66.7%)
Phase 23 (33.3%)

Trials by Status

completed778%
terminated222%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

NCT02861300
completedphase_2

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217
terminatedphase_1

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

NCT02771626
completedphase_2

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

NCT03057600
completedphase_2

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

NCT03163667
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02861300Phase 1

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Completed
NCT03428217Phase 2

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Completed
NCT02771626Phase 1

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Terminated
NCT03057600Phase 2

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Completed
NCT03163667Phase 2

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

Completed
NCT02071862Phase 1

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Completed
NCT03875313Phase 1

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Terminated
NCT02071888Phase 1

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Completed
NCT02071927Phase 1

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9